Second-line treatment for men with radiorecurrent prostate cancer (the FORECAST trial)

An ongoing clinical trial available exclusively in the UK is the so-called FORECAST trial, designed to investigate focal forms of second-line therapy for men with progressive, radiorecurrent prostate cancer after first-line treatment with external beam radiation therapy. … READ MORE …